Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab

This cohort study estimates 5-year standardized risks for any first cancer among patients being treated with biologics for moderate to severe psoriasis.

Corresponding Author: Christopher Willy Schwarz, MD, Department of Dermatology and Allergy, Copenhagen University Hospital–Herlev and Gentofte, Gentofte Hospitalsvej 15, 1st Floor, 2900 Hellerup, Denmark (christopher.willy.schwarz.01@regionh.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.